Breaking News

RVAC Medicines to Expand R&D and Mfg. Capacity

Plans to build R&D center and manufacturing facilities in Singapore and China with $140 million in funds raised.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

RVAC Medicines Pte. Ltd., an emerging messenger RNA (mRNA) platform company incubated in Singapore by CBC Group (CBC), completed its series B financing, bringing the company’s total funds raised since its inception in June 2021 to $140 million. RVAC aims to address unmet medical needs, particularly in emerging markets, through novel vaccines and therapeutics including a potential best-in-class COVID vaccine. Financing will be used for preclinical and clinical development of the company&#82...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters